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Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine
and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the
next year, they all suffer from limitations of either cost, specific toxicities or parenteral
administration. As part of research to identify better treatments for VL and cutaneous leishmaniasis
(CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines
other than miltefosine and improved formulations of paromomycin for CL have been identified.
Other drugs or compounds that have demonstrated activity in experimental rodent models of
infection include licochalcone derivatives, quinoline derivatives, bisphosphonates and a maesabalide;
further chemistry based upon these leads is warranted. The process for discovery and development
of new antileishmanials would also benefit from improved models, for example, transfected parasites,
and non invasive methods of measuring parasite load in rodent models of infection.
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The recommended drugs used for the treatment of
both visceral leishmaniasis (VL) and cutaneous
leishmaniasis (CL), the pentavalent antimonials, were
first introduced 60 yr ago. Over the past decade
alternative drugs or new formulations of other standard
drugs have become available and registered for use in
some countries, whilst other drugs are on clinical trial
for both forms of the disease. Although the ambition
to develop a single drug or drug formulation effective
against all forms of leishmaniasis is unlikely to be
fulfilled, the advances have been significant as the
concept of choice for treatment is now real. The
problems of developing a single drug or formulation
for all forms of leishmaniasis revolve around factors
that include: (i) the visceral and cutaneous sites of
infection impose differing pharmacokinetic
requirements on the drugs to be used; and (ii) the
intrinsic variation in drug sensitivity of the 17
Leishmania species known to infect humans. Other
problems to be surmounted by new treatments for
leishmaniasis are (iii) the need for drugs active in Bihar
State, India where there is acquired resistance to the
pentavalent antimonials1; and (iv) increased efficacy
in immunosuppressed patients, in particular due to
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HIV co-infection. In the latter case, where there is
exacerbation of disease or emergence from latent
infection, the depleted immune capability means that
standard chemotherapy is frequently unsuccessful2-5.
This review will gives an overview of (i) drugs
that have been recently introduced and are still in
phases of clinical trials or not widely registered, (ii)
novel compounds and drugs that have shown activity
in animal models and are worth considering for lead
optimization; and (iii) specific methodologies
involved in the discovery of new drugs.
Drugs in clinical development (Fig.)
Miltefosine: Miltefosine, initially developed as an
anticancer drug, is the first effective oral treatment
of VL and the latest antileishmanial drug to enter
the market6. Its antileishmanial activity was initially
discovered in the mid-1980s and efficacy
demonstrated in a number of experimental models
in vitro and in vivo7-9. These findings led to clinical
trials and registration in India in March 2002 (Table)
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Fig. Structures of antileishmanial drugs on clinical trial.
for oral treatment of VL and in Colombia for CL in
2005.
There are concerns about teratogenicity and the
long half-life of the drug, and that the latter might
encourage the emergence of resistance10. It has been
shown in vitro in laboratory studies on promastigotes
that miltefosine resistant lines of Leishmania
donovani can be selected11 and resistance is related
to two mutations on a transporter, the
aminophospholipid translocase LdMT12. Variation in
species sensitivity, demonstrated in vitro with
L. donovani, L. aethiopica, L. tropica, L. mexicana
and L. panamensis being more sensitive (EC50 values
between 2.63 and 10.63 µM) to miltefosine than
L. major (EC50 value 37.17 µM)13, is also a concern.
The variation, also demonstrated in clinical isolates14,
needs to be taken into account in drug use as it could
contribute to different clinical outcomes in different
regions as observed in a recent trial against CL in
Colombia and Guatemala15. In Colombia, in regions
where Leishmania vianna panamensis is common,
the cure rates for miltefosine were 91 per cent
(40 of 44 patients), whereas in Guatemala (regions
where L.v.braziliensis and L. mexicana mexicana are
common) the cure rates achieved were only 53 per
cent (20 of 38 patients) and lower than the historic
antimony cure rates of >90 per cent.
Teratogenicity, potential of resistance
development and a low therapeutic window pose
limitations on miltefosine and it is desirable to
optimize its structure with regard to activity and/or
overcoming these limitations. Thus (SAR) studies
have been carried out and a recent study explored
the influence of cycloalkane rings in the lipid portion
as well as headgroup modifications on activity
towards L. donovani and L. infantum promastigotes
and cytotoxicity towards THP-1 cells16. With regard
to headgroup SAR, choline is preferred resulting in
similar activity against both Leishmania strains,
whereas the introduction of cycloalkylidene groups
in the lipid portion results in enhanced activity, more
pronounced against L. infantum than L. donovani. The
mechanism of action of miltefosine is still not known.
Several molecular targets in trypanosomatids have
been suggested, including ether lipid metabolism,
glycophosphatidylinositol (GPI) anchor biosynthesis,
signal transduction and induction of apoptosis17-19, as
well as inhibition of an alkyl-specific acyl-CoA
acyltransferase in L. mexicana20. Miltefosine also
displayed marked activity against another
trypanosomatid, Trypanosoma cruzi, with EC50
values < 2 µM against intracellular amastigotes of
the Y strain in murine macrophages9. Further studies
on miltefosine of basic and preclinical nature are
underway, including interaction studies for the
potential use of drug combinations21.
Paromomycin: Paromomycin (PM), an
aminoglycoside antibiotic, was originally identified
as an antileishmanial in the 1960s and has been used
in clinical trials for both VL and CL. Development
of the parenteral formulation of PM, a drug with poor
oral bioavailability, for VL has been slow, but phase
III trials are currently ongoing in India under the
aegis of the Institute of One World Health
(www.iowh.org) and in East Africa managed by
DNDi and partner institutes (www.dndi.org).
As with miltefosine, resistance to paromomycin
could be induced in L. donovani promastigotes
experimentally in vitro. The resistance was specific
to PM and stable and its mechanism seems to be due
to decreased drug uptake22. Ribosomes have been
implicated as target23 and inhibition of RNA synthesis
followed by protein synthesis shown, along with
induction of respiratory dysfunction24. With PM
moving into the field more studies on the mechanism
of action and, more importantly, resistance are
required. Variation in species sensitivity in vitro has
also been demonstrated for PM with L. braziliensis
and L. mexicana being less sensitive (EC50 values
between 38 and 39.4 µM) than L. major, L. tropica
and L. panamensis (EC50 values between 0.9 and 4.9
µM)25. It is interesting to note the considerable
differences between different isolates of L. donovani
(EC50 values ranging from 6.1 to 165.7 µM)
demonstrated in the same study. Findings of this
nature could have important implications in clinical
outcome. For an Ethiopian strain (MHOM/ET/67/
L82) of L. donovani marked synergy with sodium
stibogluconate was demonstrated in vitro, to a lesser
extent against an Indian strain (MHOM/IN/82/
PATNA I). The interaction in vivo in BALB/c mice
against MHOM/ET/67/L82 was additive. A
combination of PM and sodium stibogluconate has
been the subject of various clinical trials in Sudan
and India26,27 but further studies to optimize the
combination and define drug-drug interactions are
required.
PM might also be a drug suitable for the topical
treatment of CL. The report by El-On and colleagues
in 198428 that a topical formulation containing 15 per
cent PM and 12 per cent methyl benzethonium
chloride (a skin-penetrating agent) was effective
against experimental CL led to the clinical trials. One
such trial demonstrated that 77 per cent were cured
after 20 days treatment compared with 27 per cent
cured in the placebo group29. Other topical
formulations with a lower skin irritancy have recently
been on clinical trial, including one containing 15
per cent PM with 10 per cent urea and another
containing 15 per cent PM with 0.5 per cent
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gentamicin in a 10 surfactant vehicle (WR279 396)
that cured 64 per cent of CL patients after 20 days
treatment in Colombia30. In an endemic area of Iran
the 15 per cent PM/10 per cent urea showed no
efficacy on cutaneous leishmaniasis and it was argued
that the response to PM varied with the species and
the type of lesion being treated31. These studies have
also highlighted the need for a rational
pharmaceutical design of formulations optimal for
CL and the need for species specific diagnosis32.
Amphotericin B formulations: Amphotericin B (Amp
B) in the form of amphotericin B deoxycholate
(Fungizone®) is the second-line treatment for
visceral leishmaniasis when antimonial therapy fails.
Originally developed as a systemic antifungal, it is
also an efficient antileishmanial, but has the major
drawback of being acutely toxic and thus must be
carefully administered. To ameliorate this, re-
formulations of Amp B have been developed to alter
its pharmacokinetics. By changing the serum-binding
properties, its high affinity for low density
lipoproteins (LDL) being the major cause of toxicity,
lipid associated Amp B preparations have been made
with varying degrees of success. The liposomal
amphotericin B formulation, AmBisome®, is
registered treatment for visceral leishmaniasis33, but
use in VL endemic regions is limited by cost. Other
commercial amphotericin B - lipid formulations have
also been manufactured, namely an amphotericin B
lipid complex (Abelcet®) and an amphotericin B
colloidal dispersion (Amphocil™)34 but their use
against VL has not been as extensive as AmBisome®
and they too, are costly35. Other re-formulations of
amp B formulations have been investigated against
experimental VL but none have reached clinical
development to date. Approaches to reduce cost
include: (i) efficacy trials of single dose AmBisome
treatment for VL, with 90 per cent cure rate reported
to date1, and (ii) the use of cheaper liposomal
formulations, already tried for VL36. Alternative
amphotericin B formulations have been developed.
For example, arabinogalactan derivatives36,37,
nanoparticles38,39; and other lipid formulations40, or
chemical derivatives41, have proved effective in
experimental models42,43.  The act of heating
amphotericin B to form superaggregates reduces in
vivo toxicity without loss of efficacy and warrants
further investigation as a cheap alternative to the lipid
formulations44,45. It has already been evaluated for
the treatment of canine VL46.
Novel amphotericin B formulations have been
used successfully to treat CL in immunocompromised
patients47 and paediatric CL43. However, as CL is
usually a self-limiting syndrome little effort has been
made to evaluate the use of amphotericin B as a
treatment for CL on a wider scale48.
Sitamaquine: Another oral drug that might have an
impact on VL is the 8-aminoquinoline derivative
sitamaquine, currently in development with
GlaxoSmithKline (GSK, http://www.gsk.com)49. The
antileishmanial activity of this compound was first
identified in the 1970s at the Walter Reed Army
Institute of Research (WRAIR, http://wrair-
www.army.mil/). Limited Phase I/II clinical trials
have been completed with varying levels of success,
for instance, 67 per cent of patients were cured  of
L. chagasi in Brazil when treated with 2 mg/kg daily
for 28 days50, and 92 per cent were cured of VL when
treated with 1.7 mg/kg daily for 28 days in Kenya51
and a 89 per cent cure rate with 1.75 mg/kg daily for
28 days in India52. Sitamaquine is rapidly
metabolized, forming desethyl and 4-CH2OH
derivatives, which might be responsible for its
activity. Toxicity appears to be relatively mild, it
causes mild methemoglobinaemia, and further
studies are underway on this drug.
Imiquimod :  Imiquimod (Aldara, 3M
Pharmaceuticals) is an antiviral compound [1-(2-
methylropyl)-1H-imidazo(4,5-c)quinolin-4-amine]
used extensively for the topical treatment of genital
warts caused by the human papillomavirus. It is an
immunomodulator, stimulating a local immune
response at the site of application, which in turn
resolves the infection. Imiqimod induces the
production of cytokines and nitric oxide in
macrophages and has been shown to have an effect
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in experimental infections of cutaneous
leishmaniasis53, and in conjunction with standard
antimonial chemotherapy, has been used to
successfully treat patients with cutaneous lesions
which did not respond to antimonial therapy alone54.
It is suggested that the topical treatment activates
localized macrophages to kill the parasite, while the
antimonial eliminates systemic amastigotes which
are responsible for persistence of infection55,56.
Drugs in lead optimization and preclinical
phases
Although many compounds have shown activity
in in vitro models, few have received thorough testing
in rodent models of infection. Of these, a few have
demonstrated significant antileishmanial activity in
different models. Plant products are an abundant
source of leads, evidenced in the area of
antimalarials. Licochalcone A from the Chinese
liquorice plant Glycyrrhiza has shown reasonable
oral efficacy in experimental models of VL and CL;
synthetic oxygenated derivatives are also active57.
One derivative, 35m4ac, gave 97 per cent suppression
of L. donovani liver amastigotes in a hamster model
at 20 mg/kg for 6 days i.p. The compounds appear to
interfere with mitochondrial function. Another
compound, PX-6581, from the Vietnamese plant
Maesa balansae, showed significant activity in VL
models but was not progressed due to toxicity58,59.
Further study on this series to optimize activity is
underway60. Isopropylquinolines, isolated from
Galipea longiflora in Bolivia, also showed activity
in VL and CL models61 and studies on further SAR
have recently been published62. Other quinoline
derivatives, the indolyl quinolines, have also shown
activity against VL in murine models and are the
subject of further research63.
Therapeutic switching or “piggy-back
chemotherapy” is another potential source for new
antileishmanial compounds. Azoles, originally
developed as antifungal drugs, have shown activity
against Leishmania spp. Like fungi, Leishmania
synthesize 24-substituted sterols, such as ergosterol
(mammals have cholesterol).  Azoles can inhibit a
key enzyme of this pathway, 14α-demethylase.
Ketoconazole, itraconazole and fluconazole have
given equivocal results in trials against both CL and
VL64. Oral posaconazole has shown encouraging
activity against experimental L. amazonensis65 but
this has not been developed further. Bisphosphonates,
used for the treatment of bone disorders such as
osteoporosis, are another example of therapeutic
switching. Two of these drugs, risedronate and
pamidronate, were active against experimental
infections of both CL and VL66,67.
Drug discovery and development
The overall stages of drug discovery and
development for neglected diseases, like
leishmaniasis, have been recently described68 and will
not be covered here. We will focus here on the
specific in vitro and in vivo assays required in the
drug discovery process for leishmaniasis.
In vitro assays: In an earlier review69, requirements
for an in vitro assay to indicate the intrinsic activity
of antileishmanial drugs were outlined and included
use of (i) mammalian stage of the parasite, (ii) a
dividing population, (iii) quantifiable and
reproducible measures of drug activity, and (iv)
activity of standard drugs in concentrations
achievable in serum/tissues. Recently, assay design
has focussed on features that make the assay
adaptable to medium throughput screening (MTS),
with additional requirements of (i) small amounts of
compound (<1 mg), (ii) quick throughput, and (iii)
low cost of tests. Other useful features of in vitro
assays are adaptability for studies on (i) variation of
drug sensitivity using recent isolates, different
species/strains, resistant strains, and (ii) effects of
immune or metabolic components.
For antileishmanial drug discovery in vitro assays
are available on:
(i) Promastigotes : Drug activity against this
extracellular stage is easy to determine. However,
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there are significant differences between
promastigotes and amastigotes in biochemistry and
sensitivity to standard and experimental drugs13,70-72.
Promastigotes assays are useful cytotoxicity indicators
in bioassay-guided fractionation of plant products.
(ii) Macrophage - amastigote models: The most
widely used models for testing drugs against
Leishmania species have involved either murine
peritoneal macrophages or human-monocyte
tranformed macrophages as host cells. These models
are able to show species/strain variation in drug
sensitivity13,14. In these differentiated non-dividing
macrophages the rate of amastigote division in host
cells and drug activity can be clearly determined.
Drug activity is measured by either microscopical
counting of  percentage of infected cells or number
of amastigotes/macrophage73 or colorimetric or
fluorometric methods. The slow rate of division of
L. donovani and L. infantum amastigotes in this
model is a limitation. Mouse (J774)74 and human
(THP-1, U937, HL-60) monocytic cell lines have
been used in drug assays75. Assays that use dividing
host cells must ensure that the confounding effects
of drug activity on both parasite and host cell number
are considered. THP-1 cells can form a non-dividing
monolayer and make an attractive alternative to
primary isolated macrophages, and have been used
in antibacterial assays76.
(iii) Axenic amastigotes: Axenic amastigote cultures
offer different opportunities and protocols have been
described for L. mexicana77,78, L. braziliensis79,
L. donovani80,81 and L. infantum82. However, the
amastigotes used must have confirmed biochemical
and immunological markers and interpretation of data
related to the high concentration of serum that is
required in some systems. Differences in drug
sensitivity between axenic L. donovani amastigotes
and intracellular amastigotes have been observed81.
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Table. Current drugs used for the treatment of leishmaniasis
Visceral leishmaniasis
First line drugs Sodium stibogluconate (Pentostam, SSG); meglumine antimoniate (Glucantime)
Amphotericin B (Fungizone)
Liposomal amphotericin B (AmBisome)
Pentamidine
Clinical trials Miltefosine (oral, Phase IV; registered in India )
Paromomycin (Phase III)
Sitamaqine (oral, Phase II)
Other amphotericin B formulations
Cutaneous leishmaniasis:
First line drugs Sodium stibogluconate (Pentostam); meglumine antimoniate (Glucantime)
Amphotericin B (Fungizone)
Pentamidine
Paromomycin (topical formulations with methylbenzethonium chloride or urea)
Clinical trials Miltefosine (oral, Phase III, registered in Colombia)
Paromomycin (topical formulation with gentamicin and surfactants, Phase II)
Imiquimod (topical immunomodulator, Phase II)
Also anti-fungal azoles – ketoconazole, fluconazole, itraconazole
Parenteral administration unless otherwise stated
(iv) Automated screening: A major limitation of the
amastigote-macrophage model is that the absence of
automation and dependence on microscopical
evaluation. Promastigote assays using reazzurin
(Alamar Blue) and transfected parasites have been
successful83,84 but not within the clinically relevant
amastigote-macrophage model.  Various groups have
successfully transfected reporter genes into
Leishmania, however, the majority of them require
drug selection to maintain the plasmid, as in
Trypanosoma cruzi85. This is not ideal for use in drug
experiments.  Recently the firefly luciferase gene has
been successfully integrated into the genome of a
L. amazonensis strain and has been evaluated in vitro.
It was used in a drug-screening assay in 96-well
plates and compared favourably with microscopical
evaluation85. Transfected reference strains of
Leishmania, such as L. donovani HU3, would be of
further use to the drug screening community and
work is underway to achieve this.
In vivo assays: Animal models enable drug activity
to be determined in relation to absorption (route of
administration), distribution (different sites of
infection), metabolism (pro-drugs,
immunomodulators), excretion and to give an early
indication of the toxicity. Most of the models use
mice, where a relatively low amount of compound is
required, which are available as SPF and inbred
strains enabling reproducible results with five
animals/group. Mice are susceptible to most strains
and species of Leishmania in both non-cure and self-
cure models. The aim of using the animal model is
to find a drug that can be administered orally, be
effective in a short course (< 10 days) and have no
indication of toxicity at the highest doses tested (100
mg/kg). (i) For visceral leishmaniasis inbred strains
of mice are widely used with susceptible, resistant
and intermediate strains being available. The
BALB/c mouse is a commonly used strain, at 18-
20 g, with highly reproducible levels of infection
when an amastigote inoculum is administered i.v..
An assay in week two after infection examines the
activity of the drug against the liver infection but
not the spleen infection. The infection in each mouse
strain needs to be characterized for each parasite
strain used to ensure that drugs are tested
appropriately. Athymic and scid mice provide a
model for treatment of VL in immunosuppressed
cases87,88. The hamster is also a good model for VL
and provides a more synchronous infection in the
liver and spleen that can develop into a chronic non-
cure infection more similar to human VL. However,
the weight (50-60 g), the absence of an easy route
for i.v. inoculation and the limited availability of
inbred SPF animals make this model less predictable.
A problem in all the models is the determination of
drug activity upon necropsy or biopsy which has been
dependent on microscopy to determine the level of
infection. This is now being replaced by quantitative
PCR techniques90. (ii) For cutaneous leishmaniasis
inbred strains of mice are available with defined
susceptibility/resistance, cure and non-cure to
L. major, L. mexicana and L. panamensis. The
BALB/c mouse - L. major model has been used
widely in drug studies but it is an exceptionally
rigorous non-cure model in which only the most
active drugs have any efficacy and absolute cure is
rare. In this model the standard antimonial drugs are
ineffective. Other mouse models (CBA, C57/Bl) that
self-cure, like most humans, should be used for
studies on lead compounds90. Lesions on the back of
mice are also amenable for testing topical
formulations. The determination of drug efficacy by
measuring changes in lesion size (three dimensions)
during and after the course of treatment can be
misleading as much of the lesion is composed of
inflammatory cells with amastigotes restricted to
dermal layer of the skin. Culturing parasites from
biopsies provides an alternative measurement of
activity and has been shown to give quantitative
data91,92. However, PCR methodologies have been
introduced that give quantitative and reproducible
data93,94.  Poor animal models for L. tropica,
L. aethiopica and L. braziliensis are a limitation for
studies. Recent work on the L. braziliensis hamster
model has shown potential for drug testing95.
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Concluding remarks
The drug discovery pipeline for leishmaniasis is
imbalanced. With data from the genome project
complied with interest from key researchers in
biochemistry and chemistry, there has been renewed
interest in drug discovery. Projects have identified
many hits and leads. However, like in many areas of
drug research, the tools, models and skills available
to progress these compounds through the lead
optimization and pre-clinical stages are limited.
Along with efforts to find new compounds, resources
availability is essential at this crucial stage of drug
development to key groups and centres.
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